NewAmsterdam Pharma (NAMS) Receivables - Other (2023 - 2025)
NewAmsterdam Pharma's Receivables - Other history spans 3 years, with the latest figure at $6.8 million for Q4 2025.
- For Q4 2025, Receivables - Other rose 287.01% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $6.8 million, up 287.01%, while the annual FY2025 figure was $6.8 million, 287.01% up from the prior year.
- Receivables - Other for Q4 2025 was $6.8 million at NewAmsterdam Pharma, up from $3.9 million in the prior quarter.
- Across five years, Receivables - Other topped out at $6.8 million in Q4 2025 and bottomed at $875000.0 in Q4 2023.
- The 3-year median for Receivables - Other is $2.1 million (2024), against an average of $2.9 million.
- The largest YoY upside for Receivables - Other was 287.01% in 2025 against a maximum downside of 63.81% in 2025.
- A 3-year view of Receivables - Other shows it stood at $875000.0 in 2023, then soared by 99.77% to $1.7 million in 2024, then soared by 287.01% to $6.8 million in 2025.
- Per Business Quant, the three most recent readings for NAMS's Receivables - Other are $6.8 million (Q4 2025), $3.9 million (Q3 2025), and $3.3 million (Q2 2025).